Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genscript
Pharma
Merck and BioNTech's I-O bispecific buys—Fierce Pharma Asia
Merck and BioNTech bought Chinese biotechs to gain bispecifics. AZ and Daiichi refiled their TROP2 antibody-drug conjugate with the FDA. And more.
Angus Liu
Nov 15, 2024 8:20am
GenScript sets up operations and logistics center in Australia
Nov 11, 2024 10:59am
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Oct 25, 2024 8:43am
Legend sheds GenScript as its majority shareholder
Oct 23, 2024 7:26am
J&J partner Legend Biotech reportedly receives buyout offer
Jul 15, 2024 11:06am
Daiichi-Merck, Wegovy, Takeda CEO—Fierce Pharma Asia
Jun 28, 2024 8:40am
